ADPT Adaptive Biotechnologies

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: . The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS

Karina Calzadilla, Vice President, Investor Relations

201-396-1687

ADAPTIVE MEDIA

Erica Jones, Associate Director, Corporate Communications

206-279-2423



EN
09/10/2024

Underlying

ADPTAdaptive Biotechnologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adaptive Biotechnologies

 PRESS RELEASE
Free
ADPT Adaptive Biotec...

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. “Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Im...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ADPT Adaptive Biotec...

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoS...

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ADPT Adaptive Biotec...

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Result...

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern ...

October 9, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 47.72
SHAK Shake Shack In...
PLAY Dave & Buster's... ... (+65)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

SHAK SHAKE SHACK INC. CLASS A
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OCUL OCULAR THERAPEUTIX
HNRG HALLADOR ENERGY CO.
EAT BRINKER INTERNATIONAL INC.
DECK DECKERS OUTDOOR CORPORATION
CSIQ CANADIAN SOLAR INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
CALM CAL-MAINE FOODS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
BBW BUILD-A-BEAR WORKSHOP
ASPN ASPEN AEROGELS
APOG APOGEE ENTERPRISES INC.
AMSC AMERICAN SUPERCONDUCTOR CORP.
ALB ALBEMARLE CORPORATION
AAOI APPLIED OPTOELECTRONICS INC.
COF CAPITAL ONE FINANCIAL CORPORATION
ZUMZ ZUMIEZ INC.
VFC V.F. CORPORATION
CRVS CORVUS PHARMACEUTICALS
DESP DESPEGAR.COM CORP.
FNKO FUNKO CLASS A
AMD ADVANCED MICRO DEVICES INC.
ACMR ACM RESEARCH
PPIH PERMA PIPE INTERNATIONAL HOLDINGS
GLOB GAZIT-GLOBE LTD.
PLMR PALOMAR HOLDINGS
CAPR CAPRICOR THERAPEUTICS
CRMD CORMEDIX INC.
BILL BILL.COM HOLDINGS
ADPT ADAPTIVE BIOTECHNOLOGIES
GII SPDR S&P GLOBAL INFRASTRUCTURE
TVTX TRAVERE THERAPEUTICS INC
VHI VALHI INC.
ALKT ALKAMI TECHNOLOGY INC
SOFI SOFI TECHNOLOGIES INC
EVGO EVGO INC
ENVX ENOVIX CORP
TSE TRINSEO PLC
ASTS AST SPACEMOBILE INC
PLL PIEDMONT LITHIUM INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
RDW REDWIRE CORP
COYA COYA THERAPEUTICS INC
SKWD SKYWARD SPECIALTY INS GROUP INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
WGS GENEDX HOLDINGS CORP.
KGS KODIAK GAS SERVICES INC
BYRN BYRNA TECHNOLOGIES INC
NMRA NEUMORA THERAPEUTICS INC
ATGL ALPHA TECHNOLOGY GROUP LTD
NGNE NEUROGENE INC
DAVE DAVE INC
LENZ LENZ THERAPEUTICS INC
IBTA IBOTTA INC
FIP FTAI INFRASTRUCTURE INC
CLMT CALUMET INC
NUTX NUTEX HEALTH INC
DOGZ DOGNESS INTERNATIONAL CORP
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
TBNK TD CANADIAN BANK DIVIDEND INDEX ETF
RDDT REDDIT INC
10/08/24 October 8, 2024 1 EN
 PRESS RELEASE
Free
ADPT Adaptive Biotec...

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Adaptive Announces IVDR Certification for clonoSEQ® in European Union clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ® has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). The me...

August 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch